Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing reassessment of Nauclea officinalis extract syrup in children with acute upper respiratory tract infection
ChiCTR1800016745Phase 4Completed
- Sponsor
- West China Second University Hospital
- Start
- Jun 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of nauclea officinalis extract in upper respiratory infection (URI) (2 arms), sponsored by West China Second University Hospital. Primary endpoint: Recovery time of major symptoms complete remission. Started Jun 2018; status: completed.
02
Drugs
nauclea officinalis extract
03
Conditions
upper respiratory infection (URI)
Beyond the preview
Go deeper on ChiCTR1800016745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016745.